Semaglutide and Early Metabolism Problems in People with Schizophrenia Spectrum Disorders: A Randomized Trial

Conflict of Interest Disclosures: Dr Sass reported institution received unrestricted grants from Novo Nordisk A/S, Mental Health Services in the Capital Region of Denmark, The Lundbeck Foundation, the Novo Nordisk Foundation, and P. Carl Petersen Foundation and being a full-time employee of Novo Nordisk A/S outside the submitted work. Dr Schwarz reported receiving personal fees from Novo Nordisk and Eli Lilly outside the submitted work. Dr Rasmussen reported receiving a pregraduate fellowship grant from Novo Nordisk Foundation during the conduct of the study. Dr Giver reported receiving grants from Novo Nordisk during the conduct of the study. Dr Hviid reported receiving grants from Dagmar Foundation and The Lundbeck Foundation during the conduct of the study. Dr Schilling reported institution received grants from Novo Nordisk A/S, Mental Health Services in the Capital Region of Denmark, The Lundbeck Foundation, Novo Nordisk Foundation, and P. Carl Petersen Foundation during the conduct of the study. Dr Gefke reported receiving grants from Jascha Foundation during the conduct of the study. Dr Kjaer reported receiving consultant fees from Novo Nordisk A/S outside the submitted work. Dr Holst reported receiving grants from Novo Nordisk Foundation during the conduct of the study. Dr Vinberg reported receiving grants from Jascha Foundation during the conduct of the study. Dr Correll reported receiving royalties from UpToDate; consultant and/or advisor fees from AbbVie, Alkermes, Allergan, Angelini, Aristo, Autobahn, Boehringer Ingelheim, Bristol Meyers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Draig, Eli Lilly, Eumentis Therapeutics, Gedeon Richter, GH, Hikma, Holmusk, Intra-Cellular Therapies, Jamjoom Pharma, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedInCell, Med-Link, Merck, Mindpax, Mitsubishi Tanabe Pharma, Maplight, Mylan, Neumora Therapeutics, Neuraxpharm, Neurocrine, Neurelis, NeuShen, Newron, Noven, Novo Nordisk, Orion Pharma, Otsuka, PPD Biotech, Recognify Life Science, Recordati, Relmada, Response Pharmaceutical, Re-viva, Rovi, Saladax, Sanofi, Seqirus, Servier, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva, Terran, Tolmar, Vertex, Viatris and Xenon Pharmaceuticals; providing expert testimony for Janssen, Lundbeck, Neurocrine, and Otsuka; serving on a Data Safety Monitoring Board for Compass Pathways, Intra-Cellular Therapies, Relmada, Reviva, and Rovi; receiving grant support from Boehringer-Ingelheim, Janssen, and Takeda; and having stock options for Cardio Diagnostics, Kuleon Biosciences, LB Pharma, MedLink Global, Mindpax, Quantic, and Terran. Dr Vilsbøll reported receiving advisory fees from Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Gilead, GSK, Mass Medicine, Novo Nordisk, Carmot/Roche, Regor, Sanofi, Sun Pharmaceuticals, and Zealand Pharma Global outside the submitted work. Dr Fink-Jensen reported receiving an unrestricted research grant from Novo Nordisk A/S during the conduct of the study and serving as an unpaid member of the advisory board for Novo Nordisk A/S outside the submitted work. No other disclosures were reported.